Notch2 signaling promotes osteoclast resorption via activation of PYK2

Cellular Signalling

Volumn 28, Issue 5, 2016, Pages 357-365

  Jin, Won Jong ^a   Kim, Bongjun ^a   Kim, Jung Wook ^a   Kim, Hong Hee ^a   Ha, Hyunil ^b   Lee, Zang Hee ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Dibenzazepine; Notch2; Osteoclast; PYK2; Resorption

Indexed keywords

FOCAL ADHESION KINASE 2; INTERLEUKIN 1; MEMBRANE PROTEIN; NICD2 PROTEIN; NOTCH2 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; DIBENZAZEPINE; DIBENZAZEPINE DERIVATIVE; ENZYME INHIBITOR; NFATC1 PROTEIN, MOUSE; NOTCH2 PROTEIN, MOUSE; PTK2B PROTEIN, MOUSE; SECRETASE; TRANSCRIPTION FACTOR NFAT;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; GENE OVEREXPRESSION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL DIFFERENTIATION; CHEMISTRY; DRUG EFFECTS; DRUG THERAPY; ENZYME ACTIVATION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY; PROTEIN DOMAIN;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DIBENZAZEPINES; ENZYME ACTIVATION; ENZYME INHIBITORS; FOCAL ADHESION KINASE 2; MALE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTEIN DOMAINS; RECEPTOR, NOTCH2; SIGNAL TRANSDUCTION;

EID: 84957956929     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.01.016     Document Type: Article

References (42)

1. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling. emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 1995, 332:305-311.
2. Galson D.L., Roodman G.D. Pathobiology of Paget's disease of bone. J. Bone Metab. 2014, 21:85-98.
3. Hirayama T., Danks L., Sabokbar A., Athanasou N.A. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:1232-1239.
4. Boyce B.F. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J. Bone Miner. Res. 2013, 28:711-722.
5. Kim S.H., Moon S.H. Osteoclast differentiation inhibitors: a patent review (2008-2012). Expert Opin. Ther. Pat. 2013, 23:1591-1610.
6. Kodama H., Nose M., Niida S., Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 1991, 173:1291-1294.
7. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
8. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
9. Fuller K., Owens J.M., Jagger C.J., Wilson A., Moss R., Chambers T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J. Exp. Med. 1993, 178:1733-1744.
10. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 1999, 190:1741-1754.
11. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3:889-901.
12. Akisaka T., Yoshida H., Inoue S., Shimizu K. Organization of cytoskeletal F-actin, G-actin, and gelsolin in the adhesion structures in cultured osteoclast. J. Bone Miner. Res. 2001, 16:1248-1255.
13. Teitelbaum S.L. The osteoclast and its unique cytoskeleton. Ann. N. Y. Acad. Sci. 2011, 1240:14-17.
14. Gil-Henn H., Destaing O., Sims N.A., Aoki K., Alles N., Neff L., et al. Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-mice. J. Cell Biol. 2007, 178:1053-1064.
15. Lakkakorpi P.T., Bett A.J., Lipfert L., Rodan G.A., Duong L.T. PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-src, osteoclast spreading, and bone resorption. J. Biol. Chem. 2003, 278:11502-11512.
16. Sanjay A., Houghton A., Neff L., DiDomenico E., Bardelay C., Antoine E., et al. Cbl associates with Pyk2 and src to regulate src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 2001, 152:181-195.
17. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64:693-702.
18. Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W.C., Baron R. Src kinase activity is essential for osteoclast function. J. Biol. Chem. 2004, 279:17660-17666.
19. Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin. Cell Dev. Biol. 1998, 9:583-589.
20. Lai E.C. Notch signaling: control of cell communication and cell fate. Development 2004, 131:965-973.
21. Duan L., Ren Y. Role of notch signaling in osteoimmunology-from the standpoint of osteoclast differentiation. Eur. J. Orthod. 2013, 35:175-182.
22. Bai S., Kopan R., Zou W., Hilton M.J., Ong C.T., Long F., et al. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J. Biol. Chem. 2008, 283:6509-6518.
23. Fukushima H., Nakao A., Okamoto F., Shin M., Kajiya H., Sakano S., et al. The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol. Cell. Biol. 2008, 28:6402-6412.
24. Ashley J.W., Ahn J., Hankenson K.D. Notch signaling promotes osteoclast maturation and resorptive activity. J. Cell. Biochem. 2015, 116:2598-2609.
25. Kim S.D., Kim H.N., Lee J.H., Jin W.J., Hwang S.J., Kim H.H., et al. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Biochem. Pharmacol. 2013, 86:782-790.
26. Lee J.H., Kim H.N., Yang D., Jung K., Kim H.M., Kim H.H., et al. Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J. Biol. Chem. 2009, 284:13725-13734.
27. Jin W.J., Kim B., Kim J.-W., Kim H.-H., Ha H., Lee Z.H. Inhibition of notch signaling involvement in osteoclast differentiation and spreading. Data in Brief 2016.
28. McHugh K.P., Hodivala-Dilke K., Zheng M.H., Namba N., Lam J., Novack D., et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 2000, 105:433-440.
29. Lakkakorpi P.T., Nakamura I., Young M., Lipfert L., Rodan G.A., Duong L.T. Abnormal localisation and hyperclustering of (alpha)(V)(beta)(3) integrins and associated proteins in src-deficient or tyrphostin A9-treated osteoclasts. J. Cell Sci. 2001, 114:149-160.
30. Boyce B.F., Yoneda T., Lowe C., Soriano P., Mundy G.R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 1992, 90:1622-1627.
31. Zou W., Kitaura H., Reeve J., Long F., Tybulewicz V.L., Shattil S.J., et al. Syk, c-src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 2007, 176:877-888.
32. Croke M., Ross F.P., Korhonen M., Williams D.A., Zou W., Teitelbaum S.L. Rac deletion in osteoclasts causes severe osteopetrosis. J. Cell Sci. 2011, 124:3811-3821.
33. Izawa T., Zou W., Chappel J.C., Ashley J.W., Feng X., Teitelbaum S.L. c-Src links a RANK/alphavbeta3 integrin complex to the osteoclast cytoskeleton. Mol. Cell. Biol. 2012, 32:2943-2953.
34. Dikic I., Tokiwa G., Lev S., Courtneidge S.A., Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 1996, 383:547-550.
35. Sekine C., Koyanagi A., Koyama N., Hozumi K., Chiba S., Yagita H. Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res. Ther. 2012, 14:R45.
36. Duong L.T., Lakkakorpi P.T., Nakamura I., Machwate M., Nagy R.M., Rodan G.A. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J. Clin. Invest. 1998, 102:881-892.
37. Jurdic P., Saltel F., Chabadel A., Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur. J. Cell Biol. 2006, 85:195-202.
38. Destaing O., Saltel F., Gilquin B., Chabadel A., Khochbin S., Ory S., et al. A novel rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts. J. Cell Sci. 2005, 118:2901-2911.
39. Andersen P., Uosaki H., Shenje L.T., Kwon C. Non-canonical notch signaling: emerging role and mechanism. Trends Cell Biol. 2012, 22:257-265.
40. Hodkinson P.S., Elliott P.A., Lad Y., McHugh B.J., MacKinnon A.C., Haslett C., et al. Mammalian NOTCH-activates beta1 integrins via the small GTPase R-ras. J. Biol. Chem. 2007, 282:28991-29001.
41. Abramson S.B., Amin A. Blocking the effects of IL-in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002, 41:972-980.
42. Lorenzo J.A., Naprta A., Rao Y., Alander C., Glaccum M., Widmer M., et al. Mice lacking the type I interleukin-receptor do not lose bone mass after ovariectomy. Endocrinology 1998, 139:3022-3025.